BROOKS LABORATORIES LIMITED (BROOKS): Financials & Fundamentals History

Share Price

₹60.56

P/E

13.5x

ROCE

21.0%

Market Cap

₹178 cr

Revenue (TTM)

₹83 cr

P/S

2.1x

P/B

1.5x

ROE

10.8%

Operating Margin

-5.8%

Debt / Equity

0.1x

Promoter Holding

52.6%

12M Momentum

-45.4%

52-week range

₹36.30₹123.00

28% of the way from its 52-week low to its high

Price risk

1Y volatility

69.8%

Beta vs sector

1-year daily

0.87

Balance sheet & cash

Interest cover

operating profit ÷ interest

18.9x

Share count, 1Y

unchanged

Was the rally earned?

-45%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

Per-share earnings added 176 points, but investors now pay less per rupee of profit (P/E 258.0x to 13.5x), which took 221 points back.
The share count barely moved.

Net profit growth+176 ptsNet profit rose about 944%, which lifts the price.

P/E change-221 ptsThe P/E fell from 258.0x to 13.5x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

What is the price implying?

~11%annual earnings growth implied by the price

At a P/E of 13.5x, the price would imply about 10.8%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

What changed?

Jun '26Moved into the 2nd quartile of Health Technology on ROCE (from the bottom quartile).
Mar '26Fell 81% from the Jan 2025 peak to the Mar 2026 low.
Mar '26Slipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
Dec '25Revenue (TTM) reached a new high of ₹93 cr.
Sep '25EPS (TTM) turned positive.
Sep '25Moved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
Jun '25Promoter holding fell 6.4 pts to 52.6%.
Jun '25FII + DII holding rose 6.6 pts over 1 quarter to 10.4%.

Show 15 earlier events

Jun '25Share count is up 11.5% over 12 months.
Mar '25Promoter holding fell 4.5 pts to 59.1%.
Dec '24Regained the 2024-01 peak, 6 months after the low.
Jun '24Fell 58% from the Jan 2024 peak to the Jun 2024 low.
Dec '23Regained the 2021-09 peak, 7 months after the low.
May '23Fell 62% from the Sep 2021 peak to the May 2023 low.
Jun '22Revenue (TTM) reached a new high of ₹91 cr.
Apr '21Regained the 2021-01 peak, 1 month after the low.
Mar '21Fell 29% from the Jan 2021 peak to the Mar 2021 low.
Dec '20Regained the 2020-10 peak, 1 month after the low.
Nov '20Fell 27% from the Oct 2020 peak to the Nov 2020 low.
Sep '20Regained the 2019-02 peak, 6 months after the low.
Mar '20Fell 76% from the Feb 2019 peak to the Mar 2020 low.
Feb '19Regained the 2019-01 peak, 0 months after the low.
Feb '19Fell 35% from the Jan 2019 peak to the Feb 2019 low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Are profits backed by cash?

3 of 6 checks are within range, 1 near a threshold, 2 beyond a threshold.
Tap a check to see how it is measured.

Other income reliance98%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 98.2%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate0%Beyond threshold

Median quarterly effective tax rate over about 2.5 years: 0.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow2 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 2. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-6 daysWithin range

Debtor days are below the median of the previous three fiscal years by 6 days (69 vs 75). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress7% of fixed assetsWithin range

Capital work-in-progress is 7% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-17 days / 2 yrsWithin range

Days payable changed by -17 over two years. Bands: rise of up to 30 days; more than 30 days.

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 2 years, promoters trimmed 11.0 pts; DIIs added 6.5 pts.
The number of shareholders rose from 10,028 to 11,161 (+11%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change

Promoters63.6%52.6%-11.0 pts

FIIs0.0%0.0%0.0 pts

DIIs3.9%10.4%+6.5 pts

Public and others32.6%37.0%+4.4 pts

Number of shareholders

11,161shareholders+11% since Dec '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

How rough has the ride been?

Maximum drawdown-81.0%not yet recovered

1-year volatility69.8%annualised

Monthly share price

Last 90 trading days

Drawdown from peak

Largest drawdowns

-81.0% (2025-01 peak to 2026-03 low, not yet recovered)

-76.2% (2019-02 peak to 2020-03 low, recovered 2020-09)

-61.5% (2021-09 peak to 2023-05 low, recovered 2023-12)

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Nov '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Oct '26

Lower rank Higher rank

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What happened next to similar setups

+1.5%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like BROOKS LABORATORIES LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −22% to +34% vs the market, against 0% for all non-financial companies in the same months.
The gap against the base rate (+1.4%, 80% range −8.3% to +12.3%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 7 beyond the range shown, drawn at the edge

Similar setups' median

+1.5%

All companies' median

+0.1%

Beat the market

52% vs 50%

50 past situations · 50 companies · 37 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
MMP Non-Energy Minerals	Jul 2020	9x	13%	−40%	−49%	+53%
ALANKIT Technology Services	Jan 2022	25x	17%	+5%	−34%	−41%
AKSHARCHEM Process Industries	Jan 2020	8x	27%	−41%	−46%	−6%
CANARYS Technology Services	Oct 2024	29x	20%	−5%	−37%	−32%
MPSLTD Consumer Services	Nov 2020	10x	17%	−25%	−29%	+41%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
KOPRAN Health Technology	May 2023	12x	21%	−32%	−33%	+2%
INTENTECH Technology Services	Jul 2022	8x	28%	−35%	−38%	+1%
BALAXI Health Technology	Mar 2025	13x	21%	−36%	−55%	−75%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and P/E. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to BROOKS LABORATORIES LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-10-30. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 97,430 company-months from 2000 companies; financial: 5,632 company-months from 106 companies. 2240 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Monthly history (65 months)

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-10	13.5x	₹83 cr	10.8%	21.0%	0.1x
2026-09	12.4x	₹83 cr	10.8%	21.0%	0.1x
2026-08	8.0x	₹86 cr	20.1%	21.0%	0.1x
2026-07	7.3x	₹86 cr	20.1%	21.0%	0.1x
2026-06	8.2x	₹86 cr	20.1%	21.0%	0.1x
2026-05	8.9x	₹89 cr	22.0%	-10.0%	0.1x
2026-04	7.6x	₹89 cr	22.0%	-10.0%	0.1x
2026-03	5.1x	₹89 cr	22.0%	-10.0%	0.1x
2026-02	14.4x	₹93 cr	14.3%	-10.0%	0.1x
2026-01	13.2x	₹93 cr	14.3%	-10.0%	0.1x
2025-12	17.2x	₹93 cr	14.3%	-10.0%	0.1x
2025-11	237.7x	₹90 cr	1.3%	-10.0%	0.1x
2025-10	258.0x	₹90 cr	1.3%	-10.0%	0.1x
2025-09	312.2x	₹90 cr	1.3%	-10.0%	0.1x
2025-08	—	₹83 cr	-10.2%	-10.0%	0.1x
2025-07	—	₹83 cr	-10.2%	-10.0%	0.1x
2025-06	—	₹83 cr	-10.2%	-10.0%	0.1x
2025-05	—	₹77 cr	-27.9%	-25.0%	0.1x
2025-04	—	₹77 cr	-27.9%	-25.0%	0.1x
2025-03	—	₹77 cr	-27.9%	-25.0%	0.1x
2025-02	—	₹78 cr	-30.6%	-25.0%	0.1x
2025-01	—	₹78 cr	-30.6%	-25.0%	0.1x
2024-12	—	₹78 cr	-30.6%	-25.0%	0.1x
2024-11	—	₹82 cr	-27.0%	-25.0%	0.1x
2024-10	—	₹82 cr	-27.0%	-25.0%	0.1x
2024-09	—	₹82 cr	-27.0%	-25.0%	0.1x
2024-08	—	₹79 cr	-30.2%	-25.0%	0.1x
2024-07	—	₹79 cr	-30.2%	-25.0%	0.1x
2024-06	—	₹79 cr	-30.2%	-25.0%	0.1x
2024-05	—	₹63 cr	-41.9%	-30.0%	0.1x
2024-04	—	₹63 cr	-41.9%	-30.0%	0.1x
2024-03	—	₹63 cr	-41.9%	-30.0%	0.1x
2024-02	—	₹63 cr	-41.9%	-30.0%	0.1x
2024-01	—	₹63 cr	-41.9%	-30.0%	0.1x
2023-12	—	₹63 cr	-41.9%	-30.0%	0.1x
2023-11	—	₹63 cr	-41.9%	-30.0%	0.1x
2023-10	—	₹63 cr	-41.9%	-30.0%	0.1x
2023-09	—	₹63 cr	-41.9%	-30.0%	0.1x
2023-08	—	₹63 cr	-41.9%	-30.0%	0.1x
2023-07	—	₹63 cr	-41.9%	-30.0%	0.1x
2023-06	—	₹63 cr	-41.9%	-30.0%	0.1x
2023-05	—	₹91 cr	-21.6%	-16.0%	0.3x
2023-04	—	₹91 cr	-21.6%	-16.0%	0.3x
2023-03	—	₹91 cr	-21.6%	-16.0%	0.3x
2023-02	—	₹91 cr	-21.6%	-16.0%	0.3x
2023-01	—	₹91 cr	-21.6%	-16.0%	0.3x
2022-12	—	₹91 cr	-21.6%	-16.0%	0.3x
2022-11	—	₹91 cr	-21.6%	-16.0%	0.3x
2022-10	—	₹91 cr	-21.6%	-16.0%	0.3x
2022-09	—	₹91 cr	-21.6%	-16.0%	0.3x
2022-08	—	₹91 cr	-21.6%	-16.0%	0.3x
2022-07	—	₹91 cr	-21.6%	-16.0%	0.3x
2022-06	—	₹91 cr	-21.6%	-16.0%	0.3x
2022-05	—	₹77 cr	-24.1%	—	0.4x
2022-04	—	₹77 cr	-24.1%	—	0.4x
2022-03	—	₹77 cr	-24.1%	—	0.4x
2022-02	—	₹77 cr	-24.1%	—	0.4x
2022-01	—	₹77 cr	-24.1%	—	0.4x
2021-12	—	₹77 cr	-24.1%	—	0.4x
2021-11	—	₹77 cr	-24.1%	—	0.4x
2021-10	—	₹77 cr	-24.1%	—	0.4x
2021-09	—	₹77 cr	-24.1%	—	0.4x
2021-08	—	₹77 cr	-24.1%	—	0.4x
2021-07	—	₹77 cr	-24.1%	—	0.4x
2021-06	—	₹77 cr	-24.1%	—	0.4x

Methodology and data notes